MX388170B - Polimorfos de selinexor - Google Patents

Polimorfos de selinexor

Info

Publication number
MX388170B
MX388170B MX2017002013A MX2017002013A MX388170B MX 388170 B MX388170 B MX 388170B MX 2017002013 A MX2017002013 A MX 2017002013A MX 2017002013 A MX2017002013 A MX 2017002013A MX 388170 B MX388170 B MX 388170B
Authority
MX
Mexico
Prior art keywords
structural formula
crystalline forms
compound
selinexor
polymorphs
Prior art date
Application number
MX2017002013A
Other languages
English (en)
Other versions
MX2017002013A (es
Inventor
Brian Clinton Austad
David G Roe
Original Assignee
Karyopharm Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karyopharm Therapeutics Inc filed Critical Karyopharm Therapeutics Inc
Publication of MX2017002013A publication Critical patent/MX2017002013A/es
Publication of MX388170B publication Critical patent/MX388170B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion se refiere a formas cristalinas del compuesto representado por la Formula estructural I y a composiciones que comprenden formas cristalinas del compuesto representado por la Formula estructural I descrita en la presente. Las formas cristalinas del compuesto de Formula estructural I y las composiciones que comprenden las formas cristalinas del compuesto de Formula estructural I proporcionadas en la presente, en particular, la Forma cristalina unica A, se pueden incorporar en composiciones farmaceuticas, las cuales se pueden utilizar para tratar varios trastornos asociados con la actividad de CRM1, incluido el cancer. En la presente tambien se describen metodos para preparar el compuesto de Formula estructural I y sus formas cristalinas unicas.
MX2017002013A 2014-08-15 2015-08-14 Polimorfos de selinexor MX388170B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462038069P 2014-08-15 2014-08-15
PCT/US2015/045395 WO2016025904A1 (en) 2014-08-15 2015-08-14 Polymorphs of selinexor

Publications (2)

Publication Number Publication Date
MX2017002013A MX2017002013A (es) 2017-05-12
MX388170B true MX388170B (es) 2025-03-19

Family

ID=53969460

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017002013A MX388170B (es) 2014-08-15 2015-08-14 Polimorfos de selinexor
MX2021014128A MX2021014128A (es) 2014-08-15 2017-02-14 Polimorfos de selinexor.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021014128A MX2021014128A (es) 2014-08-15 2017-02-14 Polimorfos de selinexor.

Country Status (18)

Country Link
US (6) US10519139B2 (es)
EP (2) EP4112615A1 (es)
JP (3) JP6777626B2 (es)
KR (1) KR102608259B1 (es)
CN (3) CN111484483B (es)
AU (4) AU2015301484B2 (es)
CA (1) CA2957266A1 (es)
CO (1) CO2017001884A2 (es)
DK (1) DK3180331T3 (es)
EA (1) EA201790384A1 (es)
ES (1) ES2926377T3 (es)
IL (1) IL250328B (es)
MA (1) MA40254B1 (es)
MX (2) MX388170B (es)
SG (2) SG10201808624VA (es)
UA (1) UA123535C2 (es)
WO (1) WO2016025904A1 (es)
ZA (1) ZA201700880B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2954991T3 (es) 2011-07-29 2023-11-28 Karyopharm Therapeutics Inc Moduladores del transporte nuclear que contienen hidrazida y usos de los mismos
SMT202000347T1 (it) 2012-05-09 2020-07-08 Biogen Ma Inc Modulatori di trasporto nucleare e loro usi
WO2014144772A1 (en) 2013-03-15 2014-09-18 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
PL3010892T3 (pl) 2013-06-21 2019-07-31 Karyopharm Therapeutics, Inc. 1,2,4-triazole jako modulatory transportu jądrowego i ich zastosowania
CN111484483B (zh) 2014-08-15 2023-05-26 卡尔约药物治疗公司 赛灵克斯的多晶型物
EP3397634A1 (en) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
EP3397633A1 (en) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
US11034675B2 (en) 2016-01-08 2021-06-15 Dr. Reddy's Laboratories Limited Solid forms of Selinexor and process for their preparation
US11602530B2 (en) 2016-11-28 2023-03-14 Biogen Ma Inc. CRM1 inhibitors for treating epilepsy
EP3565813A1 (en) 2017-01-05 2019-11-13 Watson Laboratories, Inc. Novel crystalline forms of selinexor and process for their preparation
CN106831731B (zh) * 2017-01-17 2019-11-08 广州市闻皓生物科技有限公司 一种Selinexor原料药的合成方法
WO2019232724A1 (en) 2018-06-06 2019-12-12 Xw Laboratories, Inc. Compounds as nuclear transport modulators and uses thereof
WO2020072008A1 (en) * 2018-10-04 2020-04-09 Deva Holding Anonim Sirketi Novel solid dispersions of selinexor
JP2022524741A (ja) 2019-03-20 2022-05-10 ジョンソン、マッセイ、パブリック、リミテッド、カンパニー セリネクソールの共結晶形態
CA3135712A1 (en) * 2019-05-01 2020-11-05 Brian Clinton AUSTAD Process for preparing xpo1 inhibitors and intermediates for use in the preparation of xp01 inhibitors
EP3968987A4 (en) * 2019-05-16 2022-10-26 Mayo Foundation for Medical Education and Research METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
EP3808742A1 (en) 2019-10-16 2021-04-21 Sandoz AG Polymorph of selinexor
US20230391754A1 (en) 2020-10-21 2023-12-07 Karyopharm Therapeutics Inc. Crystalline form of selinexor
CN112679477B (zh) * 2020-12-17 2021-10-26 佛山奕安赛医药科技有限公司 塞利尼索及其中间体的制备方法
EP4452525A4 (en) * 2021-12-20 2026-01-07 Rtx Corp IMPROVEMENT OF CERAMIC MATRIX COMPOSITE PARTICLES, ITS MANUFACTURING PROCESS AND ARTICLES COMPRISING THEM
CN116675677B (zh) * 2023-08-02 2023-09-26 中国林业科学研究院林产化学工业研究所 一种c8漆酚衍生物及其制备方法和应用

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1017398A (en) 1911-01-16 1912-02-13 John E Folsom Telegraph-key.
CS229934B2 (en) 1981-07-07 1984-07-16 Pfizer Production method subst.indolylacryte acid derivative
KR840000529A (ko) 1981-07-07 1984-02-25 콘스탄틴 루이스 클레멘트 인돌 유도체의 제조방법
US4778796A (en) 1985-07-19 1988-10-18 Dainippon Pharmaceutical Co., Ltd. ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same
JP3111321B2 (ja) 1990-02-23 2000-11-20 武田薬品工業株式会社 縮合チアゾール化合物
IL97249A (en) 1990-02-23 1995-01-24 Takeda Chemical Industries Ltd Compounds of 7,6,5,4-tetrahydrothiazole] B-5,4 [pyridine and compounds of 5,6-dihydro-H4-pyrrolo] D-3,2 [thiazole, their manufacture, and pharmaceutical compositions including or
US5541213A (en) 1993-06-24 1996-07-30 Eisai Co., Ltd. Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility
US5468353A (en) 1994-05-05 1995-11-21 Minnesota Mining And Manufacturing Company Mist suppressant for solvent extraction metal electrowinning
BR9509760A (pt) 1994-11-23 1998-06-30 Neurogen Corp Composto
US20030018025A1 (en) 1995-06-07 2003-01-23 Neurogen Corporation, Corporation Of The State Of Delaware Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands
JPH11513382A (ja) 1995-10-20 1999-11-16 ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング ５員複素環化合物、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法
US6214818B1 (en) 1996-04-04 2001-04-10 Shionogi & Co., Ltd. Cephem compounds and pharmaceutical compositions containing the same
EP1360901A1 (en) 1996-04-25 2003-11-12 Nissan Chemical Industries, Limited 2,3-cyclic substituted derivatives of 3-hydroxyacrolein and 3-hydroxyacrylic acid as pesticides
JP4054992B2 (ja) 1996-04-25 2008-03-05 日産化学工業株式会社 エチレン誘導体および有害生物防除剤
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
US5994398A (en) 1996-12-11 1999-11-30 Elan Pharmaceuticals, Inc. Arylsulfonamides as phospholipase A2 inhibitors
JP4416198B2 (ja) 1997-12-19 2010-02-17 武田薬品工業株式会社 アニリド誘導体、その製造法および用途
AU2960599A (en) 1998-03-30 1999-10-18 Akira Karasawa Quinazoline derivatives
US6743585B2 (en) 1999-09-16 2004-06-01 Agilent Technologies, Inc. Methods for preparing conjugates
CO5271680A1 (es) 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
ATE310719T1 (de) 2000-09-29 2005-12-15 Topotarget Uk Ltd Carbaminsäurederivate enthaltend eine amidgruppe als hdac-inhibitoren
JP3795044B2 (ja) 2001-09-14 2006-07-12 メシルジーン、インコーポレイテッド ヒストンデアセチラーゼの阻害剤
AU2003287965A1 (en) 2002-10-24 2004-05-13 Carex Sa Modulation of peroxisome proliferator activated receptors activity
DE10250743A1 (de) 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
PL376733A1 (pl) 2002-11-01 2006-01-09 Takeda Pharmaceutical Company Limited Środek do zapobiegania lub leczenia neuropatii
JP4145230B2 (ja) 2002-11-01 2008-09-03 武田薬品工業株式会社 神経障害の予防・治療剤
US7342115B2 (en) 2002-11-08 2008-03-11 Neurogen Corporation 3-substituted-6-aryl pyridines
WO2004076418A1 (en) 2003-02-28 2004-09-10 Galderma Research & Development, S.N.C. Ligands that modulate lxr-type receptors
CA2566094A1 (en) 2004-05-26 2005-12-08 Eisai R & D Management Co., Ltd. Cinnamide compound
AU2005272389B2 (en) 2004-08-11 2011-08-04 Kyorin Pharmaceutical Co., Ltd. Novel cyclic aminobenzoic acid derivative
WO2006019020A1 (ja) 2004-08-16 2006-02-23 Sankyo Company, Limited 置換されたウレア化合物
US20100130737A1 (en) 2005-02-18 2010-05-27 Takeda Pharmaceutical Company Limited Regulating Agent of GPR34 Receptor Function
US8637559B2 (en) 2005-11-15 2014-01-28 Otsuka Pharmaceutical Co., Ltd. Oxazole compound and pharmaceutical composition
JP2007210929A (ja) 2006-02-09 2007-08-23 Sankyo Co Ltd ウレア化合物を含有する医薬
PL1992618T3 (pl) 2006-03-09 2012-06-29 Eisai R&D Man Co Ltd Policykliczna pochodna cynamidowa
WO2007118137A1 (en) 2006-04-07 2007-10-18 Methylgene Inc. Benzamide derivatives as inhibitors of histone deacetylase
NZ572268A (en) 2006-04-18 2011-09-30 Nippon Chemiphar Co Activating agent for peroxisome proliferator activated receptor delta (ppar)
JP4999923B2 (ja) 2006-06-13 2012-08-15 中国科学院上海薬物研究所 複素環非ヌクレオシド系化合物、抗ウィルス医薬組成物、及びウィルス性疾病治療薬物
CA2658925C (en) 2006-07-27 2015-07-14 Amorepacific Corporation Novel sulfonylamino acrylamide derivatives, isomer thereof,or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
JP4388997B2 (ja) 2006-09-05 2009-12-24 協和発酵キリン株式会社 イミダゾール誘導体
EP1939180A1 (en) 2006-12-20 2008-07-02 sanofi-aventis Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
EP1942104A1 (en) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
CN101711154A (zh) 2007-02-26 2010-05-19 科森生物科学公司 氨基甲酸酯化合物
EP2003118A1 (de) 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Zimtsäurederivate als Modulatoren des EP2-Rezeptors
WO2010017545A2 (en) 2008-08-08 2010-02-11 Synta Pharamceuticals Corp. Triazole compounds that modulate hsp90 activity
MX2012000434A (es) 2009-07-09 2012-04-11 Crescendo Therapeutics Llc Metodo de sanacion de herida y modulacion de cicatriz.
US8518968B2 (en) 2009-12-04 2013-08-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hydrazone and diacyl hydrazine compounds and methods of use
CN103002742B (zh) 2010-03-05 2016-07-13 卡尔约药物治疗公司 核转运调节剂及其应用
JP6106605B2 (ja) 2011-01-17 2017-04-05 カリオファーム セラピューティクス，インコーポレイテッド オレフィン含有核輸送調節剤およびその使用
CA2842364A1 (en) 2011-07-29 2013-02-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
ES2954991T3 (es) * 2011-07-29 2023-11-28 Karyopharm Therapeutics Inc Moduladores del transporte nuclear que contienen hidrazida y usos de los mismos
WO2013020024A2 (en) 2011-08-03 2013-02-07 Karyopharm Therapeutics, Inc. Maleimide compounds and methods of treatment
SMT202000347T1 (it) 2012-05-09 2020-07-08 Biogen Ma Inc Modulatori di trasporto nucleare e loro usi
WO2014152263A1 (en) 2013-03-15 2014-09-25 Karyopharm Therapeutics Inc. Exo olefin-containing nuclear transport modulators and uses thereof
WO2014144772A1 (en) 2013-03-15 2014-09-18 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
PL3010892T3 (pl) 2013-06-21 2019-07-31 Karyopharm Therapeutics, Inc. 1,2,4-triazole jako modulatory transportu jądrowego i ich zastosowania
WO2014205393A1 (en) 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
WO2015073908A1 (en) * 2013-11-15 2015-05-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method for selecting cancer treatment regimen
JP6805137B2 (ja) 2014-07-11 2020-12-23 アンセルム（アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） 血液学的癌を診断するための方法
WO2016015598A1 (en) * 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
CN111484483B (zh) 2014-08-15 2023-05-26 卡尔约药物治疗公司 赛灵克斯的多晶型物
CN108348547B (zh) 2015-08-28 2023-09-22 纽约市哥伦比亚大学信托人 用于匹配肿瘤学特征的系统和方法
EP3397634A1 (en) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
EP3397633A1 (en) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
US11034675B2 (en) * 2016-01-08 2021-06-15 Dr. Reddy's Laboratories Limited Solid forms of Selinexor and process for their preparation
JP6765198B2 (ja) 2016-03-10 2020-10-07 パナソニック株式会社 潜熱蓄熱材及びそれを用いる蓄熱システム
US11602530B2 (en) 2016-11-28 2023-03-14 Biogen Ma Inc. CRM1 inhibitors for treating epilepsy
EP3565813A1 (en) * 2017-01-05 2019-11-13 Watson Laboratories, Inc. Novel crystalline forms of selinexor and process for their preparation
CN106831731B (zh) 2017-01-17 2019-11-08 广州市闻皓生物科技有限公司 一种Selinexor原料药的合成方法
PH12021552349A1 (en) 2019-03-27 2022-09-12 Karyopharm Therapeutics Inc Biomarkers for selinexor
EP3808742A1 (en) 2019-10-16 2021-04-21 Sandoz AG Polymorph of selinexor
GB2591846B (en) 2019-12-06 2024-08-14 Bae Systems Plc Light source
US20230391754A1 (en) 2020-10-21 2023-12-07 Karyopharm Therapeutics Inc. Crystalline form of selinexor

Also Published As

Publication number Publication date
UA123535C2 (uk) 2021-04-21
AU2021286266B2 (en) 2024-02-01
US11807629B2 (en) 2023-11-07
JP6777626B2 (ja) 2020-10-28
KR20170043561A (ko) 2017-04-21
IL250328A0 (en) 2017-03-30
AU2020203246A1 (en) 2020-06-04
AU2020203246B2 (en) 2021-09-16
AU2024202835A1 (en) 2024-05-23
ES2926377T3 (es) 2022-10-25
US11078190B2 (en) 2021-08-03
US12371420B2 (en) 2025-07-29
CN111481553B (zh) 2023-09-01
JP2023052622A (ja) 2023-04-11
US11753401B2 (en) 2023-09-12
DK3180331T3 (da) 2022-09-12
CO2017001884A2 (es) 2017-07-19
ZA201700880B (en) 2020-01-29
US20230242516A1 (en) 2023-08-03
US20220135545A1 (en) 2022-05-05
CA2957266A1 (en) 2016-02-18
EA201790384A1 (ru) 2017-08-31
EP3180331B1 (en) 2022-06-08
CN107072992B (zh) 2020-03-10
JP2020143144A (ja) 2020-09-10
CN111484483A (zh) 2020-08-04
JP7558310B2 (ja) 2024-09-30
AU2021286266A1 (en) 2022-01-06
MA40254A (fr) 2021-05-19
IL250328B (en) 2022-05-01
AU2015301484A1 (en) 2017-03-02
US11746102B2 (en) 2023-09-05
KR102608259B1 (ko) 2023-11-29
WO2016025904A1 (en) 2016-02-18
AU2015301484B2 (en) 2020-02-20
US20230242517A1 (en) 2023-08-03
US20200283419A1 (en) 2020-09-10
JP2017527549A (ja) 2017-09-21
US20180215733A1 (en) 2018-08-02
EP3180331A1 (en) 2017-06-21
EP4112615A1 (en) 2023-01-04
US20240208943A1 (en) 2024-06-27
MX2021014128A (es) 2022-01-04
CN111481553A (zh) 2020-08-04
CN107072992A (zh) 2017-08-18
MA40254B1 (fr) 2022-09-30
JP7218323B2 (ja) 2023-02-06
US10519139B2 (en) 2019-12-31
NZ728850A (en) 2024-03-22
MX2017002013A (es) 2017-05-12
SG11201700789SA (en) 2017-02-27
CN111484483B (zh) 2023-05-26
SG10201808624VA (en) 2018-11-29

Similar Documents

Publication Publication Date Title
MX388170B (es) Polimorfos de selinexor
EA201691442A1 (ru) N-азаспироциклоалканзамещенные n-гетероарильные соединения и композиции для ингибирования активности shp2
BR112017010354A2 (pt) compostos de triazolopirimidina e usos dos mesmos
MX376122B (es) Composiciones de plinabulina.
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
MX376283B (es) Compuestos de imidazopiridazina.
PH12017500089B1 (en) Aldosterone synthase inhibitors
PH12017500595B1 (en) Aldosterone synthase inhibitors
BR112017009289A2 (pt) métodos de administrar composições de amantadina
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
EA033342B1 (ru) Пирролидинкарбоксамидо производные и способы их получения и их применение
DOP2019000021A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
EA201700356A1 (ru) Новые циклопропанбензофуранилпиридопиразиндионы
PH12015502717B1 (en) Anti-fibrogenic compounds, methods and uses thereof
EA201591449A1 (ru) Способы получения противораковых композиций
GB2564185A (en) Process for the preparation of derivatives of benzodioxole
PH12015502703A1 (en) Pharmaceutical compositions
NZ767083A (en) Polymorphs of selinexor
EA201892188A1 (ru) Соединения пирролотриазина в качестве ингибиторов tam
IN2014MU00070A (es)
EA201691191A1 (ru) Полиморфные формы n-карбамоилметил-4(r)-фенил-2-пирролидона